When evaluating talent in a portfolio company, it's crucial to assess executives based on the organization's immediate, foundational needs. Focusing on aspirational, future-state capabilities can lead to neglecting critical basics, creating significant operational and financial risks.

When Emix Biopharma's CMO was revealed to be a fugitive, the company's response was a simple 8K filing claiming it wasn't a material event. This minimal, dismissive approach to a major crisis made the company look amateurish and untrustworthy, serving as a masterclass in what not to do.

During due diligence, firms identify "single points of failure"—employees who are the only ones that understand a critical system. They'll even ask about dangerous hobbies like skydiving or swimming with sharks to quantify this "key person risk" and understand potential vulnerabilities.

Shkreli dismisses BPC-157 by applying a pharma diligence framework: questioning its origin (a single researcher), lack of independent verification, implausible physiological basis, and history of failed clinical trials. This provides a clear checklist for evaluating fringe medical compounds from an industry insider's perspective.

Investors evaluate risk differently based on a company's stage. For early-stage ventures, the primary question is clinical risk: 'will the drug work?'. CMC and manufacturing are secondary. However, for late-stage (Phase 3) companies, manufacturing readiness becomes a critical diligence area where a two-year delay could be fatal.

A common failure mode for well-funded biotechs is growing headcount too rapidly. Immunocore's CEO advises new leaders to pace themselves, emphasizing that drug development is a marathon. Prematurely scaling creates fixed expenses that can drain capital before key scientific milestones are hit.

According to Novartis's CEO, a top reason for rejecting potential biotech partners is their underinvestment in Chemistry, Manufacturing, and Controls (CMC). Startups often neglect this unglamorous work, leading to deal failure because the acquirer can't be sure the drug can be scaled efficiently and safely.

An expert reveals two shocking statistics: 80% of new founders fail their first diligence attempt, and 85% of early-stage investors don't perform confirmatory diligence. This highlights a massive, systemic weakness and inefficiency in the startup ecosystem, creating significant risk on both sides of the table.

A common mistake in biotech investing is relying too heavily on a company's own data and presentations. To gain a true edge, investors should spend more time diligencing competitor drugs and the broader market landscape, as companies rarely provide an unbiased view of their competition.